Share This Page

Newsmaker: Dr. Herbert Zeh III

| Thursday, Oct. 18, 2012, 12:02 a.m.
The Alliance for Cancer Gene Therapy has named Dr. Herbert Zeh III, a UPMC surgical oncologist, its 2012 ACGT Investigator. Zeh is receiving a $500,000 grant with the award. That will help him continue his research into gene therapy for pancreatic cancer. His team is looking into how a modified virus can produce hormones that help combat cancer and cancer recurrence.

Noteworthy: The Alliance for Cancer Gene Therapy has named Zeh, a surgical oncologist at UPMC, its 2012 ACGT Investigator. A two-year, $500,000 grant from the alliance will support his gene-therapy research to combat pancreatic cancer.

Residence: Hampton

Age: 45

Family: Wife, Kelly; son, Ryan, 20; daughters, Makenzie, 15, and Teegan, 13

Occupation: Chief, Division of Gastrointestinal Surgical Oncology at UPMC CancerCenter; co-director, UPMC Pancreatic Cancer Center and the University of Pittsburgh Cancer Institute GI Oncology Program

Background: For six years, Zeh has co-directed the Pancreatic Cancer Center, one of the largest pancreatic cancer treatment facilities in the United States.

Education: Bachelor's degree in biology and philosophy, 1989, University of Notre Dame; doctorate in medicine, 1994, University of Pittsburgh

Quote: “Unfortunately, still in 2012, most patients who develop this disease will succumb to it. ... It's the highest mountain out there.”

— Adam Smeltz

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.